{"id":"doi:10.1007/s00428-018-2484-0","kind":"review","title":"Adoptive cellular therapies: the current landscape","authors":["Rohaan MW","Wilgenhof S","Haanen JBAG"],"author_count":3,"year":2019,"published":"2018-11-23","venue":"Virchows Archiv : an international journal of pathology","cited_by":303,"doi":"10.1007/s00428-018-2484-0","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1007/s00428-018-2484-0","archive_url":"https://space-kitty.com/papers/doi:10.1007/s00428-018-2484-0","updated":null,"pmid":"30470934","pmcid":"PMC6447513","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC6447513/pdf","abstract":"For many cancer types, the immune system plays an essential role in their development and growth. Based on these rather novel insights, immunotherapeutic strategies have been developed. In the past decade, immune checkpoint blockade has demonstrated a major breakthrough in cancer treatment and has currently been approved for the treatment of multiple tumor types. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) or gene-modified T cells expressing novel T cell receptors (TCR) or chimeric antigen receptors (CAR) is another strategy to modify the immune system to recognize tumor cells and thus carry out an anti-tumor effector function. These treatments have shown promising results in various tumor types, and multiple clinical trials are being conducted worldwide to further optimize this treatment modality. Most successful results were obtained in hematological malignancies with the use of CD19-directed CAR T cell therapy and already led to the commercial approval by the FDA. This review provides an overview of the developments in ACT, the associated toxicity, and the future potential of ACT in cancer treatment.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Adoptive cellular therapies: the current landscape\" by Rohaan MW, Wilgenhof S, Haanen JBAG, https://doi.org/10.1007/s00428-018-2484-0, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}